KRAS and neoplasm: In patients with a KRAS wild type tumor, the median PFS was 10.3 vs. 11.4 months (p = 0.882) for nonusers compared to statin users, and in the KRAS mutant group 7.6 vs. 6.2 months (p = 0.291), respectively.